Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-10

Study Completion Date

2022-07-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test results while treated with tolvaptan, were permanently discontinued from the drug for that reason, and subsequently completed study PA-ADPKD-303, the open-label lead-in study with lixivaptan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114

Hemodialysis Hypertension Left Ventricular Hypertrophy

TERMINATED PHASE3

Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05870007

Autosomal Dominant Polycystic Kidney Disease Chronic Kidney Diseases

ENROLLING_BY_INVITATION PHASE2

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01336972

Autosomal Dominant Polycystic Kidney Disease

COMPLETED PHASE2

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

NCT02847624

Polycystic Kidney, Autosomal Dominant

COMPLETED

Eplerenone, ACE Inhibition and Albuminuria

NCT00315016

Diabetic Nephropathy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test results while treated with tolvaptan that resulted in permanent discontinuation of tolvaptan for that reason, and subsequently completed study PA-ADPKD-303, the open-label lead-in study with lixivaptan.

Assessments completed during the final 4 visits of PA-ADPKD-303, the lead-in study, will serve as the screening and baseline assessments for this roll-over study. Evaluation of eligibility will be completed at Visit 1 of this study, following signing of informed consent. Participants satisfying all study entry criteria at Visit 1 will be considered enrolled following completion of all Visit 1 study procedures and will be dispensed lixivaptan treatment to start the Lixivaptan Re-titration Period (1 to 2 weeks). During the Lixivaptan Re-titration Period, participants will have their dose of lixivaptan re-established based on the dose they were receiving at the completion of the lead-in study. Participants will continue on lixivaptan treatment for up to 104 weeks during the Maintenance Treatment Period and will be assessed at a study visit every 12 weeks. In between the quarterly study visits, participants will be required to have blood drawn for liver chemistry determinations every 4 weeks. At the end of 104 weeks, lixivaptan treatment will be stopped, and participants will enter a 4-week Follow-up Period during which final assessments of safety and efficacy will be obtained over 3 visits during a 28-day period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Kidney Disease, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single group, open-label study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lixivaptan

Lixivaptan capsules 100-200mg twice daily

Group Type EXPERIMENTAL

Lixivaptan

Intervention Type DRUG

Oral vasopressin V2 receptor antagonist

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lixivaptan

Oral vasopressin V2 receptor antagonist

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants with ADPKD who completed study PA-ADPKD-303
* Continued control of hypertension without the use of a diuretic
* Continued adherence to prohibitions on concomitant medications stated in the study PA-ADPKD-303 protocol
* Willing to practice acceptable methods of birth control (both males who have partners of child-bearing potential and females of childbearing potential).
* Able to provide informed consent.

Exclusion Criteria

* Any contraindication to continued treatment with lixivaptan
* Clinically significant incontinence, overactive bladder, or urinary retention (e.g., benign prostatic hyperplasia)
* New York Heart Association Functional Class 3 or 4 heart failure or other significant cardiac or electrocardiogram (ECG) findings that could pose a safety risk to the participant
* Hypovolemia on physical examination at Screening
* The following laboratory results based on serum drawn at Visit 24 of PA-ADPKD-303:

* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values \>1.5 × ULN
* Total bilirubin values \>1.5 × ULN
* eGFR \<20 mL/min/1.73 m\^2 based on laboratory results from Visit 26 of PA-ADPKD-303
* A finding at Screening that precludes safe participation in the study or participants who are likely to be non-compliant with study procedures in the opinion of the Investigator or medical monitor

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No